When the brain is injured in an accident, the damage continues to spread in the following days. Blood clots are obviously to blame for this as a research team of the University of Würzburg has found.
Causes include falls during sports accidents or vehicle accidents: Traumatic brain injury is the most common cause of death and permanent disability in teenagers and young adults. In survivors, the brain damages usually worsen directly after the accident. So far, there are no therapeutic options available to prevent this development.
A possible solution is described by Würzburg scientists under the leadership of Professors Anna-Leena Sirén (experimental neurosurgery) and Christoph Kleinschnitz (neurology) in the magazine "Annals of Neurology": According to the researchers, inhibition of blood coagulation factor XII might stop the brain damage from progressing further.
Tissue samples provided the decisive cue
How did the researchers come to this conclusion? "We investigated tissue samples of patients with traumatic brain injury provided by Uppsala University with which we cooperate in the European research association CnsAflame," Sirén explains. It turned out that blood clots in the patients' brains clog blood vessels with particular frequency.
The research team believed that this is the reason why the brain damage spreads. They studied the mechanism in mice whose blood does not coagulate because the factor XII is missing. "Clogged blood vessels and post-traumatic subsequent damage were reduced significantly here," biologist Dr. Christiane Albert-Weißenberger explains. Suppressing the blood coagulation using rHA-Infestin-4, a factor XII inhibitor from CSL Behring GmbH (Marburg), also had a protective effect.
What is more: "We did not observe any bleeding when using the inhibitor. This is crucial for the drug's safe application," explains pharmacist Sarah Hopp-Krämer, who wrote her doctoral thesis on this topic in the working group of Christoph Kleinschnitz. Bleeding is a frequent complication in traumatic brain injury. Therefore, therapeutic drugs must not under any circumstances trigger bleeding.
Still a long way to clinical application
The team's conclusion: The new findings are an important step towards developing new therapies for patients suffering from craniocerebral injuries. "The patients' tissue samples have provided valuable information in this regard," Kleinschnitz further. But he predicts that several more years will pass until accident victims can potentially benefit from the new knowledge, because further tests have to be conducted to study the long-term effect of the inhibitor rHA-Infestin-4, among others. The scientists hope to continue their long-standing collaboration with the Marburg-based company for this purpose.
Sponsors of the research project
The research project was financed by the EU-funded CnsAflame research association through the Else-Kröner-Fresenius Foundation, CSL Behring GmbH and the University of Würzburg's Interdisciplinary Center for Clinical Research.
“Targeting Coagulation Factor XII as a Novel Therapeutic Option in Brain Trauma“, Sarah Hopp, Christiane Albert-Weissenberger, Stine Mencl, Michael Bieber, Michael K. Schuhmann, Christian Stetter, Bernhard Nieswandt, Peter M. Schmidt, Camelia-Maria Monoranu, Irina Alafuzoff, Niklas Marklund, Marc W. Nolte, Anna-Leena Sirén, and Christoph Kleinschnitz, Annals of Neurology, DOI: 10.1002/ana.24655
Prof. Dr. Anna-Leena Sirén, Department of Neurology of the Würzburg University Hospital, Phone +49 931 201-24579, firstname.lastname@example.org
Prof. Dr. Christoph Kleinschnitz, Department of Neurology of the Würzburg University Hospital, Phone: +49 931 201-23755, email@example.com
Robert Emmerich | Julius-Maximilians-Universität Würzburg
Lung images of twins with asthma add to understanding of the disease
06.12.2019 | University of Western Ontario
Between Arousal and Inhibition
06.12.2019 | Albert-Ludwigs-Universität Freiburg im Breisgau
University of Texas and MIT researchers create virtual UAVs that can predict vehicle health, enable autonomous decision-making
In the not too distant future, we can expect to see our skies filled with unmanned aerial vehicles (UAVs) delivering packages, maybe even people, from location...
With ultracold chemistry, researchers get a first look at exactly what happens during a chemical reaction
The coldest chemical reaction in the known universe took place in what appears to be a chaotic mess of lasers. The appearance deceives: Deep within that...
Abnormal scarring is a serious threat resulting in non-healing chronic wounds or fibrosis. Scars form when fibroblasts, a type of cell of connective tissue, reach wounded skin and deposit plugs of extracellular matrix. Until today, the question about the exact anatomical origin of these fibroblasts has not been answered. In order to find potential ways of influencing the scarring process, the team of Dr. Yuval Rinkevich, Group Leader for Regenerative Biology at the Institute of Lung Biology and Disease at Helmholtz Zentrum München, aimed to finally find an answer. As it was already known that all scars derive from a fibroblast lineage expressing the Engrailed-1 gene - a lineage not only present in skin, but also in fascia - the researchers intentionally tried to understand whether or not fascia might be the origin of fibroblasts.
Fibroblasts kit - ready to heal wounds
Research from a leading international expert on the health of the Great Lakes suggests that the growing intensity and scale of pollution from plastics poses serious risks to human health and will continue to have profound consequences on the ecosystem.
In an article published this month in the Journal of Waste Resources and Recycling, Gail Krantzberg, a professor in the Booth School of Engineering Practice...
03.12.2019 | Event News
15.11.2019 | Event News
15.11.2019 | Event News
06.12.2019 | Earth Sciences
06.12.2019 | Life Sciences
06.12.2019 | Information Technology